This was reported by the press service of the Russian Direct Investment Fund. 

"Turkmenistan became the first country in Central Asia to officially approve the use of the Sputnik V vaccine on its territory," the RDIF quoted TASS as saying.

As the head of the RDIF Kirill Dmitriev noted, Turkmenistan highly appreciated the safety and efficiency of Sputnik V.

Earlier, the Russian Ministry of Health announced that Turkmenistan is interested in purchasing Sputnik V.

In October, the head of the laboratory of the state collection of viruses at the Gamaleya Center, Inna Dolzhikova, in an interview with URA.RU, spoke about the Sputnik V vaccine.